Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy
University of Geneva · Harvard University · +11 more institutions
Abstract
T cells, are important parameters for the control of tumor growth and response to immunotherapy. Here, we show in murine and human cancers that these parameters exhibit circadian oscillations, driven by both the endogenous circadian clock of leukocytes and rhythmic leukocyte infiltration, which depends on the circadian clock of endothelial cells in the tumor microenvironment. To harness these rhythms therapeutically, we demonstrate that efficacy of chimeric antigen receptor T cell therapy and immune checkpoint blockade can be improved by adjusting the time of treatment during the day. Furthermore, time-of-day-dependent T cell signatures in murine tumor models predict overall survival in patients with melanoma…
Citation impact
- FWCI
- 44.76
- Percentile
- 100%
- References
- 66
Authors
27Topics & keywords
- Biology
- Circadian rhythm
- Immunotherapy
- Tumor microenvironment
- CD8
- Immune system
- Immunology
- Melanoma
- Good health and well-being
Funding
- NSNational Science Foundation
- CRCancer Research Institute
- MRMelanoma Research Alliance
- LILudwig Institute for Cancer Research
- OFOlivia Fund
- EFEuropean Foundation for the Study of Diabetes
- SNSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungAwards: 310030_182417/1, 310030_185255, 310030L_208130, P5R5PM_203164, P400PM_183852, PR00P3_179727, 310030_184708/1
- FWFonds Wetenschappelijk OnderzoekAward: G0B4620N
- KLKU LeuvenAwards: C14/19/098, C3/22/022, C14/19
- NNNovo Nordisk
- OKOnderzoeksraad, KU Leuven
- VIVlaamse Interuniversitaire Raad
- FLFondation Leenaards
- UDUniversité de Genève
- PUPeking University
- VVontobel-Stiftung
- GVGertrude von Meissner-Stiftung
- KOKom op tegen KankerAward: KOTK/2018/11509/1
- VRVlaamse regering
- FNFondation Novartis Consumer Health
- OMOlga Mayenfisch Stiftung
- SLSwiss Life Stiftung für Chancenreichtum und Zukunft
- FIFondation ISREC
- VVLIRUOSAward: iBOF/21/048
- NINational Institutes of HealthAwards: P01-CA240239, R01-CA218579
- IOInstitute of Genetics and Genomics of Geneva